<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384019</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-001</org_study_id>
    <nct_id>NCT01384019</nct_id>
  </id_info>
  <brief_title>Distal Protection Device in ST-elevation Myocardial Infarction (STEMI)</brief_title>
  <official_title>Distal Protection Device Did Not Improve Microvascular Obstruction Evaluated by Cardiac MR After Primary Percutaneous Intervention for ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators examined the mechanism underlying the lack of benefit from distal
      protection and thrombus aspiration (DP-TA) in 126 patients with ST-elevation Myocardial
      Infarction (STEMI) in a prospective, randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with first-diagnosed STEMI were randomly assigned to distal protection and thrombus
      aspiration (DP-TA) pretreatment during percutaneous coronary intervention (PCI) or
      conventional PCI (c-PCI).

      The primary endpoint was the remodeling index (RI), measured by cardiac magnetic resonance
      imaging (CMR) post-PCI and 6 months after PCI.

      Secondary endpoints, determined by CMR within 3 to 5 days after PCI, included the infarct
      ratio (infarct size to entire left ventricular [LV] size ) by delayed-enhancement (DE), area
      at risk (AAR) ratio (AAR to LV size) by T2 high-signal intensity , microvascular occlusion
      index (MVO) ratio (MVO to LV size) by DE, and myocardial salvage index (MSI, [AAR-infarct
      size] x 100/AAR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postinfarct Remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>postinfarct remodeling as evidenced by decreased left ventricular (LV) dilatation measured by CMR 6 months post PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reperfusion Success</measure>
    <time_frame>3-5 days</time_frame>
    <description>microvascular obstruction, myocardial salvage, and infarct size measured using post-PCI CMR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>DP-TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>c-PCI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))</intervention_name>
    <description>The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration</description>
    <arm_group_label>DP-TA</arm_group_label>
    <other_name>The GuardWire Plus (Medtronic Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>c-PCI</intervention_name>
    <description>conventional PCI without Guard wire</description>
    <arm_group_label>c-PCI</arm_group_label>
    <other_name>convenional PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 and less than 80 years presenting with STEMI

          -  more than 30 minutes but less than 12 hours after symptom onset

          -  with ≥ 2 mm of ST-segment elevation in 2 or more contiguous leads or with a presumably
             new left bundle-branch block

          -  for whom primary PCI was intended

        Exclusion Criteria:

          -  included thrombolytic therapy before PCI;

          -  spontaneous restoration of coronary flow (&gt; TIMI grade II or III);

          -  cardiogenic shock (Killip class IV);

          -  major surgery or active bleeding within 6 weeks;

          -  aspirin, thienopyridine, or heparin allergy;

          -  neutropenia (&lt;1000 neutrophils/mm3), thrombocytopenia (&lt;100000 platelets/mm3), hepatic
             dysfunction, or renal insufficiency (serum creatinine level &gt;2.5 mg/dL [221 μmol/L]);

          -  noncardiac condition with expected survival less than 1 year;

          -  current participation in other investigations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-ju Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul Natioinal University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>January 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2013</results_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>director of cardiovascular center</investigator_title>
  </responsible_party>
  <keyword>ST-elevation myocardial infarction</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>cardiac magnetic resonance imaging</keyword>
  <keyword>microvascular occlusion</keyword>
  <keyword>myocardial salvage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between Jan 24, 2004, and June 16, 2008, 550 patients with STEMI were screened.</recruitment_details>
      <pre_assignment_details>Among them, 126 patients were randomized to receive either PCI with distal protection (n=65) or PCI alone (n=61). Fifty five patients per each group received post-PCI CMR. Forty one patients underwent 6 month MRI in distal protection group and 43 patients, in conventional PCI group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DP-TA</title>
          <description>distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)</description>
        </group>
        <group group_id="P2">
          <title>c-PCI</title>
          <description>conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>MRI refusal</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DP-TA</title>
          <description>distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)</description>
        </group>
        <group group_id="B2">
          <title>c-PCI</title>
          <description>conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12"/>
                    <measurement group_id="B2" value="58" spread="11"/>
                    <measurement group_id="B3" value="58" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postinfarct Remodeling</title>
        <description>postinfarct remodeling as evidenced by decreased left ventricular (LV) dilatation measured by CMR 6 months post PCI</description>
        <time_frame>6 months</time_frame>
        <population>Forty one patients underwent 6 month CMR in distal protection group and 43 patients, in conventional PCI group.</population>
        <group_list>
          <group group_id="O1">
            <title>DP-TA</title>
            <description>distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)</description>
          </group>
          <group group_id="O2">
            <title>c-PCI</title>
            <description>conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction</description>
          </group>
        </group_list>
        <measure>
          <title>Postinfarct Remodeling</title>
          <description>postinfarct remodeling as evidenced by decreased left ventricular (LV) dilatation measured by CMR 6 months post PCI</description>
          <population>Forty one patients underwent 6 month CMR in distal protection group and 43 patients, in conventional PCI group.</population>
          <units>Number of participants with remodeling</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reperfusion Success</title>
        <description>microvascular obstruction, myocardial salvage, and infarct size measured using post-PCI CMR</description>
        <time_frame>3-5 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DP-TA</title>
          <description>distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)</description>
        </group>
        <group group_id="E2">
          <title>c-PCI</title>
          <description>conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>revascularization</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>admission due to heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chang-Hwan Yoon</name_or_title>
      <organization>Seoul national university Bundang hospital</organization>
      <phone>+82-31-787-7052</phone>
      <email>changhwanyoon@snubh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

